肝性脑病市场：按药物类别、给药途径、分销渠道、区域 - 规模、份额、前景和机会分析，2023-2030 年

肝性脑病是急性肝衰竭、肝硬化和终末期肝病患者死亡的主要原因。 肝性脑病患者丧失氨代谢能力，导致氨在身体各组织器官中蓄积。 此外，氨穿过血脑屏障，导致神经认知障碍。 肝性脑病分为隐匿性肝性脑病（CHE）和显性肝性脑病（OHE），其中显性肝性脑病比隐匿性肝性脑病（CHET）死亡率更高，据说生活质量较差。 市场进入者正在开发治疗肝病的新技术和工艺。 因此，预计来年市场将扩大。

越来越多的政府和非政府组织采取举措，以改善获得负担得起的肝臟相关治疗方案的机会。 公众对肝臟健康重要性的认识不断提高以及有利的报销是可能推动市场增长的因素。 例如，2022 年 10 月，Bausch Health Companies Inc. 及其胃肠病学业务、最大的专业製药公司之一 Salix Pharmaceuticals 宣布推出一种治疗肝性脑病 (HE) 的新药，肝性脑病是一种影响大脑的肝硬化并发症。医疗保险和医疗补助服务中心 (CMS) 实施 ICD-10 代码 K76.82

本研究的主要特点

• 本报告对全球肝性脑病市场进行了深入分析，提供了以 2022 年为基准年的预测期（2023-2030 年）的市场规模和復合年增长率 (CAGR%)。我在这里。
• 它揭示了各个细分市场的潜在收入机会，并描述了该市场有吸引力的投资主张矩阵。
• 它还提供了有关市场驱动因素、限制因素、机遇、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
• 它根据以下参数对全球肝性脑病市场的领先企业进行了介绍，包括公司亮点、产品组合、主要亮点、财务业绩和战略。
• 本研究涵盖的主要公司包括 ASKER Pharmaceutical Co., Ltd、Cosmo Pharmaceuticals N.V、Lupin Limited、Kaleido Biosciences、Kannalife Sciences Inc.、Bausch Health Companies Inc.、Ferring Pharmaceuticals In、Mallinckrodt Pharmaceuticals、Umecrine Cognition AB、 Norgine B.V、雅培实验室、QR科技发展有限公司
• 本报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
• 《全球肝性脑病市场报告》面向该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
• 利益相关者可以通过用于分析全球肝性脑病市场的各种策略矩阵来促进决策。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写

第二章市场展望

• 报告摘要
  • 市场定义和范围
• 执行摘要
  • 市场概况：按药品类别
  • 按管理途径划分的市场概况
  • 市场概况（按分销渠道）
  • 市场概况：按地区
• 连贯的机会地图 (COM)

第三章市场动态、监管与趋势分析

• 市场动态
• 驱动程序
• 制约因素
• 市场机会
• 影响分析
• 主要进展
• 最近的产品发布/批准
• 技术背景
• 合併、收购和联合研究情景
• 监管场景
• PEST分析
• 波特五力分析
• 价格分析
• 品牌分析

第 4 章肝性脑病的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

• 经济影响
• COVID-19 的流行病学
• 对供需的影响

第 5 章全球肝性脑病市场：按药物类别划分，2017-2030 年

• 抗生素
• 泻药
• L-鸟氨酸/L-天冬氨酸
• 其他

第 6 章全球肝性脑病市场：按给药途径划分，2017-2030 年

• 口服给药
• 静脉给药
• 直肠

第 7 章：全球肝性脑病市场：分销渠道，2017-2030 年

• 医院药房
• 零售药店
• 网上药店

第 8 章全球肝性脑病市场：地区，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 欧洲其他地区
• 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 东盟
• 韩国
• 亚太地区其他地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第 9 章竞争格局

• ASKA Pharmaceutical Co., Ltd
• Cosmo Pharmaceuticals N.V.
• Lupin Limited.
• Kaleido Biosciences
• Kannalife Sciences Inc.
• Bausch Health Companies Inc.
• Ferring Pharmaceuticals Inc
• Mallinckrodt Pharmaceuticals
• Umecrine Cognition AB
• Norgine B.V.
• Abbott Laboratories
• QR Science and Technology Development Co.

第 10章部分

• 调查方法
• 关于出版商

Hepatic encephalopathy (HE) is the leading cause of mortality in patients suffering from acute liver failure and also in those patients suffering from liver cirrhosis and associated with end stage liver disease. A person suffering from hepatic encephalopathy loses the ability to metabolize ammonia, which results in the buildup of ammonia in various tissues and organs of the body. Moreover, ammonia crosses the blood-brain barrier, and thus causing neurocognitive impairment. Hepatic encephalopathy can be classified into two types: covert hepatic encephalopathy (CHE) and overt hepatic encephalopathy (OHE), out of which, overt hepatic encephalopathy is associated with high rates of mortality and poor quality of life, as compared to covert hepatic encephalopathy (CHET). The major market participants have developed novel technologies and techniques for treating liver disorders. The market will expand as a result in the coming year.

Increase in the government and non-government organizations initiatives to improve access to affordable liver related treatment option. Rise in the awareness regarding the importance of liver health among the people and favorable reimbursement are the factors likely drive the market growth. For instance, in October 2022, Bausch Health Companies Inc., and its gastroenterology business, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies announced the endorsement of the implementation of K76.82, an ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE), a complication of cirrhosis that affects the brain

Key features of the study:

• This report provides in-depth analysis of the global hepatic encephalopathy market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hepatic encephalopathy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include ASKER Pharmaceutical Co., Ltd, Cosmo Pharmaceuticals N.V, Lupin Limited, Kaleido Biosciences, Kannalife Sciences Inc., Bausch Health Companies Inc, Ferring Pharmaceuticals In, Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V, Abbott Laboratories, QR Science and Technology Development Co.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatic encephalopathy market

Detailed Segmentation:

• Global Hepatic Encephalopathy Market, By Drug Class:
  • Antibiotics
  • Laxatives
  • L-ornithine L-aspartate
  • Others
• Global Hepatic Encephalopathy Market, By Route of administration:
  • Oral
  • Intravenous
  • Rectal
• Global Hepatic Encephalopathy Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hepatic Encephalopathy Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • ASKA Pharmaceutical Co., Ltd.
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Cosmo Pharmaceuticals N.V
  • Lupin Limited
  • Kaleido Biosciences
  • Kannalife Sciences Inc.
  • Bausch Health Companies Inc.
  • Ferring Pharmaceuticals Inc.
  • Mallinckrodt Pharmaceuticals
  • Umecrine Cognition AB
  • Norgine B.V
  • Abbott Laboratories
  • Kos Pharmaceuticals, Inc.
  • QR Science and Technology Development Co.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Distribution
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Drivers
• Restraints
• Market Opportunities
• Impact Analysis
• Key Developments
• Recent Product Launches/Approvals
• Technological Landscape
• Merger, Acquisition, Collaborations Scenario
• Regulatory Scenario
• PEST Analysis
• Porter's Five Forces Analysis
• Pricing Analysis
• Brand Analysis

4. Global Hepatic Encephalopathy Market - Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Hepatic Encephalopathy Market, By Drug Class, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Antibiotics
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Laxatives
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• L-ornithine L-aspartate
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Others
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends

6. Global Hepatic Encephalopathy Market, By Route of Administration, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Rectal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Hepatic Encephalopathy Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Hepatic Encephalopathy Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• China
• Japan
• India
• Australia
• ASEAN
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• ASKA Pharmaceutical Co., Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Cosmo Pharmaceuticals N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kaleido Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kannalife Sciences Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bausch Health Companies Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ferring Pharmaceuticals Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Umecrine Cognition AB
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Norgine B.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Abbott Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• QR Science and Technology Development Co.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Section

• Research Methodology
• About Us